Exosomal miRNAs from Prostate Cancer Impair Osteoblast Function in Mice.
Animals
Bone and Bones
/ metabolism
Cell Communication
Cell Line, Tumor
Cell Proliferation
Exosome Multienzyme Ribonuclease Complex
/ genetics
Exosomes
/ genetics
Extracellular Vesicles
/ metabolism
Gene Expression
/ genetics
Gene Expression Profiling
/ methods
Gene Expression Regulation, Neoplastic
/ genetics
Male
Mesenchymal Stem Cells
Mice
Mice, Inbred C57BL
MicroRNAs
/ genetics
Osteoblasts
/ physiology
Osteogenesis
Prostatic Neoplasms
/ genetics
Transcriptome
/ genetics
Tumor Microenvironment
bone metastases
extracellular vesicles
miRNA
osteoprogenitors
prostate cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
24 Jan 2022
24 Jan 2022
Historique:
received:
21
12
2021
revised:
18
01
2022
accepted:
19
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
8
3
2022
Statut:
epublish
Résumé
Prostate cancer (PCa) is the most frequent malignancy in older men with a high propensity for bone metastases. Characteristically, PCa causes osteosclerotic lesions as a result of disrupted bone remodeling. Extracellular vesicles (EVs) participate in PCa progression by conditioning the pre-metastatic niche. However, how EVs mediate the cross-talk between PCa cells and osteoprogenitors in the bone microenvironment remains poorly understood. We found that EVs derived from murine PCa cell line RM1-BM increased metabolic activity, vitality, and cell proliferation of osteoblast precursors by >60%, while significantly impairing mineral deposition (-37%). The latter was further confirmed in two complementary in vivo models of ossification. Accordingly, gene and protein set enrichments of osteoprogenitors exposed to EVs displayed significant downregulation of osteogenic markers and upregulation of proinflammatory factors. Additionally, transcriptomic profiling of PCa-EVs revealed the abundance of three microRNAs, miR-26a-5p, miR-27a-3p, and miR-30e-5p involved in the suppression of BMP-2-induced osteogenesis in vivo, suggesting the critical role of these EV-derived miRNAs in PCa-mediated suppression of osteoblast activity. Taken together, our results indicate the importance of EV cargo in cancer-bone cross-talk in vitro and in vivo and suggest that exosomal miRNAs may contribute to the onset of osteosclerotic bone lesions in PCa.
Identifiants
pubmed: 35163219
pii: ijms23031285
doi: 10.3390/ijms23031285
pmc: PMC8836054
pii:
doi:
Substances chimiques
MicroRNAs
0
Exosome Multienzyme Ribonuclease Complex
EC 3.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : uBone SPP2084
Organisme : Emmy Noether Programme
ID : TA1154/1-1
Organisme : Emmy Noether Programme
ID : TA1154/1-2
Organisme : BMBF
ID : 01ZX1910B
Références
Mol Med Rep. 2020 Sep;22(3):1717-1726
pubmed: 32705283
Trends Cancer. 2021 Feb;7(2):112-121
pubmed: 33274720
J Extracell Vesicles. 2021 Jan;10(3):e12056
pubmed: 33489015
Nucleic Acids Res. 2004 Jan 1;32(Database issue):D109-11
pubmed: 14681370
Nature. 2013 Oct 10;502(7470):232-6
pubmed: 23934107
Bonekey Rep. 2015 Jun 10;4:706
pubmed: 26131358
J Exp Med. 2019 Dec 2;216(12):2883-2899
pubmed: 31548301
Oncotarget. 2016 Jan 26;7(4):3993-4008
pubmed: 26675257
Mol Med Rep. 2016 Jul;14(1):623-9
pubmed: 27222009
Nat Protoc. 2016 Dec;11(12):2301-2319
pubmed: 27809316
Nucleic Acids Res. 2018 Jan 4;46(D1):D754-D761
pubmed: 29155950
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Oncol Lett. 2018 Oct;16(4):5291-5298
pubmed: 30250598
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):278-289
pubmed: 30669858
Bioinformatics. 2012 Jun 1;28(11):1530-2
pubmed: 22539670
Nat Rev Immunol. 2014 Mar;14(3):195-208
pubmed: 24566916
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Cancers (Basel). 2018 Jun 04;10(6):
pubmed: 29867053
Biology (Basel). 2021 Apr 10;10(4):
pubmed: 33920233
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Prostate. 2017 May;77(6):573-583
pubmed: 27990656
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nucleic Acids Res. 2012 Jan;40(1):37-52
pubmed: 21911355
Cancer Lett. 2018 Apr 28;420:228-235
pubmed: 29425686
Oncotarget. 2017 Oct 24;8(55):94834-94849
pubmed: 29212270
J Mol Histol. 2012 Oct;43(5):509-15
pubmed: 22526510
Nat Med. 2007 Jul;13(7):791-801
pubmed: 17618270
Clin Transl Med. 2021 Aug;11(8):e493
pubmed: 34459124
Future Oncol. 2011 Nov;7(11):1285-97
pubmed: 22044203
Cells. 2019 Jul 15;8(7):
pubmed: 31311206
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Bioinformatics. 2014 Oct;30(19):2811-2
pubmed: 24930139
Oncogene. 2019 Mar;38(10):1751-1763
pubmed: 30353168
Nat Rev Cancer. 2012 Jun 22;12(7):447
pubmed: 22722393
Cancer Cell. 2014 Nov 10;26(5):707-21
pubmed: 25446899
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):2204-2209
pubmed: 29440427
Nat Rev Clin Oncol. 2018 Apr;15(4):234-248
pubmed: 29405201
PLoS One. 2016 Nov 10;11(11):e0166284
pubmed: 27832183
Bioinformatics. 2005 May 1;21(9):1859-75
pubmed: 15728110
Cancer Cell. 2016 Dec 12;30(6):836-848
pubmed: 27960084
Prostate. 2009 Nov 1;69(15):1613-23
pubmed: 19585491
Cancer Res. 2005 Sep 1;65(17):7554-60
pubmed: 16140917
Cell Death Dis. 2015 Aug 06;6:e1851
pubmed: 26247736
Mol Oncol. 2014 May;8(3):689-703
pubmed: 24593875
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Nucleic Acids Res. 2016 Jan 4;44(D1):D239-47
pubmed: 26590260
J Mol Biol. 2016 Feb 22;428(4):688-692
pubmed: 26434508
Int J Biol Macromol. 2020 May 1;158:530-541
pubmed: 32360962
Front Immunol. 2019 Sep 04;10:2103
pubmed: 31555295
Nucleic Acids Res. 2019 Jan 8;47(D1):D221-D229
pubmed: 30395267
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
Mol Cell Biol. 2009 Jul;29(14):3905-14
pubmed: 19433444
Yonsei Med J. 2015 Sep;56(5):1206-12
pubmed: 26256961
Nat Cell Biol. 2015 Jun;17(6):816-26
pubmed: 25985394